Necrotizing Ulcerative Gingivitis Treatment Market Analysis

  • Report ID: 3596
  • Published Date: Jul 24, 2024
  • Report Format: PDF, PPT

Necrotizing Ulcerative Gingivitis Treatment Market Analysis

Treatment {Medication (Antiseptic Ointments, Antibiotics), Surgery (Gingival Grafting)}

The global necrotizing ulcerative gingivitis (NUG) treatment market is segmented and analyzed for demand and supply by treatment into medication which is further divided into antiseptic ointments, antibiotics, and others, and surgery which is divided into gingival grafting, and others. Out of these types, the medication segment is estimated to gain the largest market share of about 54% in the year 2036. The growth of the segment can be attributed to the increasing number of people using over-the-counter medications across the world. The rising popularity of topical applications such as antiseptic ointments and gel is estimated to hike the market growth during the forecast period. Topical applications help reduce pain, and swelling and promote a cooling effect on the apical surface which is estimated to rise the demand for medications in the coming years. Also, the rising prevalence of gingivitis elder population is estimated to fuel the market growth. More than 65% of the adult population is estimated to suffer from gingivitis across the world as of 2020. Medications such as metronidazole are the first line of drug therapy before going to any surgical procedure as it takes much time for recovery. Surgery is only preferred when the medications do not show any improvement. Antibiotics such as amoxicillin, tetracyclines, penicillin, clindamycin, and clavulanate, are used for the treatment of necrotizing ulcerative gingivitis.

Distribution Channel (Hospitals, Home Care, Pharmacies)

The global necrotizing ulcerative gingivitis (NUG) treatment market is also segmented and analyzed for demand and supply by distribution channel into hospitals, home care, pharmacies, and others. Amongst these four segments, the hospitals segment is expected to garner a significant share of around 29% in the year 2036. The treatment procedure for necrotizing ulcerative gingivitis involves regular cleaning and wiping of teeth. Also, the procedure involves hourly rinses with warm saline water or rinsing using 1.5% of hydrogen peroxide two times a day or 0.12% chlorhexidine which is usually seen in mouthwashes. This is predicted to help to remove any initial debridement present in the injury. The severe cases of necrotizing ulcerative gingivitis require all this care from the hospital to prevent further complications, hence hospital segment is estimated to drive the market growth in the coming years. The growing population with stress and sleep deprivation is also estimated to rise the prevalence of gingivitis disease which boosts the market growth in the coming years. More than 5% to 28% of adults struggle with chronic insomnia and over 29% to 50% of the elder population experience insomnia at least once as per the estimations in 2023 worldwide.

Our in-depth analysis of the global market includes the following segments:

            By Treatment

  • Medications
    • Antiseptic Ointments
    • Antibiotics
    • Others
  • Surgery
    • Gingival Grafting
    • Others

 

           By Distribution Channel

  • Hospitals
  • Home Care
  • Pharmacies
  • Others

 

Get more information on this report: Request Free Sample PDF

Browse Key Market Insights with Data Illustration:


Author Credits:  Radhika Pawar


  • Report ID: 3596
  • Published Date: Jul 24, 2024
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

In the year 2024, the industry size of necrotizing ulcerative gingivitis treatment is evaluated at USD 1.12 Billion.

The necrotizing ulcerative gingivitis treatment market size was valued at USD 1.01 Billion in 2023 and is expected to exceed USD 4.42 Billion by the end of 2036, expanding at over 12.1% CAGR during the forecast period i.e., between 2024-2036. Growing incidences of oral diseases, and poor diet and dental hygiene are the major factors driving the market growth.

North America is likely to be the largest with a share of about 32% by 2036, attributed to increasing prevalence of oral diseases in developed countries, including the US, driven by poor diet, and high cases of diabetes amongst the people.

Novartis International AG, Teva Pharmaceutical Industries Ltd., Mylan N.V., Sanofi S.A., GlaxoSmithKline plc, Merck & Co., Inc., Otsuka Pharmaceutical Co., Ltd., Abbott Laboratories, Eli Lilly and Company, Hindustan Antibiotics Limited
Inquiry Before Buying Request Free Sample
logo
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying